Travere inks bile acid divestiture; Madrigal completes NASH approval request

Travere Therapeutics is offloading its bile acid products as Mirum Pharmaceuticals picks up the rare liver disease assets for $210 million upfront.

Mirum could pay another up to $235 million in sales-based biobucks under the agreement disclosed Monday. The deal centers around the medications Cholbam and…
Click here to view original post

Advertisement — Advertise with Biotech Networks